title: The role of secretory phospholipase A₂ in the central nervous system and neurological diseases.
abstract: Secretory phospholipase A2 (sPLA2s) are small secreted proteins (14-18 kDa) and require submillimolar levels of Ca(2+) for liberating arachidonic acid from cell membrane lipids. In addition to the enzymatic function, sPLA2 can exert various biological responses by binding to specific receptors. Physiologically, sPLA2s play important roles on the neurotransmission in the central nervous system and the neuritogenesis in the peripheral nervous system. Pathologically, sPLA2s are involved in the neurodegenerative diseases (e.g., Alzheimer's disease) and cerebrovascular diseases (e.g., stoke). The common pathology (e.g., neuronal apoptosis) of Alzheimer's disease and stroke coexists in the mixed dementia, suggesting common pathogenic mechanisms of the two neurological diseases. Among mammalian sPLA2s, sPLA2-IB and sPLA2-IIA induce neuronal apoptosis in rat cortical neurons. The excess influx of calcium into neurons via L-type voltage-dependent Ca(2+) channels mediates the two sPLA2-induced apoptosis. The elevated concentration of intracellular calcium activates PKC, MAPK and cytosolic PLA2. Moreover, it is linked with the production of reactive oxygen species and apoptosis through activation of the superoxide producing enzyme NADPH oxidase. NADPH oxidase is involved in the neurotoxicity of amyloid β peptide, which impairs synaptic plasticity long before its deposition in the form of amyloid plaques of Alzheimer's disease. In turn, reactive oxygen species from NADPH oxidase can stimulate ERK1/2 phosphorylation and activation of cPLA2 and result in a release of arachidonic acid. sPLA2 is up-regulated in both Alzheimer's disease and cerebrovascular disease, suggesting the involvement of sPLA2 in the common pathogenic mechanisms of the two diseases. Thus, our review presents evidences for pathophysiological roles of sPLA2 in the central nervous system and neurological diseases.
authors.affiliation: Division of Physiology, Faculty of Pharmaceutical Sciences, Himeji Dokkyo University, 2-1-7, Kami-ohno, Himeji, Hyogo, 670-8524, Japan, yagami@himeji-du.ac.jp.
authors.forename: Tatsurou
authors.initials: T
authors.lastname: Yagami
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Yamamoto
authors.forename: Hiromi
authors.initials: H
authors.lastname: Koma
mesh_terms: D000818:Animals; D002490:Central Nervous System / Q000201:enzymology* / Q000473:pathology; D006801:Humans; D009422:Nervous System Diseases / Q000201:enzymology* / Q000473:pathology; D054497:Phospholipases A2, Secretory / Q000502:physiology*; D015398:Signal Transduction / Q000502:physiology
chemical_list: D054497:Phospholipases A2, Secretory